XtalPi Holdings (HKEX: 2228) announced receipt of a second payment of USD 19 million from US-based DoveTree Medicines under their AI-driven drug discovery collaboration. Total cash received by XtalPi under the two firms' August 2025 potential USD 5.89 billion deal total USD 70 million to date. Xtalpi also confirmed that one multi-cancer-targeted asset has entered IND-enabling research — the first concrete program to emerge from the collaboration.

The deal, struck between Shenzhen XtalPi and Cambridge, Massachusetts-based DoveTree, grants DoveTree exclusive global development and commercialization rights to all drug candidates generated through XtalPi's integrated AI and robotics platform. Financial terms include an initial payment of USD 51 million received by August 2025, up to USD 49 million in additional near-term payments — of which the USD 19 million second tranche has now been received — plus regulatory and commercial milestones totaling up to USD 5.89 billion and single-digit royalties on annual net sales.

Deal context

XtalPi, founded in 2015 by physicists from MIT and formerly known as QuantumPharm, operates an end-to-end drug discovery platform that integrates quantum mechanics-based computational modeling, generative AI, and large-scale robotic automation. The platform spans the full preclinical arc from target analysis and molecular generation through lead optimization and candidate nomination, with robotic wet-lab infrastructure embedded in the workflow rather than outsourced to CROs. Proprietary tools include the XFEP free energy perturbation engine and XMolGen generative molecular design system.

DoveTree was founded by Dr. Gregory Verdine, the Erving Professor of Chemistry at Harvard University, whose research group is associated with the development of stapled peptides and constrained molecules designed to engage historically intractable protein targets. The collaboration is explicitly oriented toward difficult-to-drug targets across oncology, immunologic and inflammatory diseases, neurological disorders, and metabolic dysregulation, with DoveTree selecting the targets and XtalPi executing discovery against them.

The lead asset described in the May 2026 announcement is characterized only as a "multi-cancer-targeted high-value asset" that has demonstrated target-specific therapeutic effects and selectivity in preliminary biological activity validation. Its molecular identity, modality, and specific target have not been disclosed. No clinical trial identifiers are available, consistent with the asset's preclinical status.

XtalPi's platform has previously supported the discovery of PEP08, a PRMT5 inhibitor developed with PharmaEngine that entered clinical trials in 2025 and has since achieved an enrollment milestone in Phase I. XtalPi's subsidiary Ailux also announced a collaboration with Eli Lilly in November 2025 to advance bispecific antibody development, extending the platform's application into biologics.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/